U.S. Markets close in 2 hrs 9 mins

Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research

Investors focused on the Medical space have likely heard of Kamada (KMDA), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Kamada is one of 847 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. KMDA is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for KMDA's full-year earnings has moved 33.33% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, KMDA has returned 22.40% so far this year. In comparison, Medical companies have returned an average of 2.36%. As we can see, Kamada is performing better than its sector in the calendar year.

Looking more specifically, KMDA belongs to the Medical - Biomedical and Genetics industry, a group that includes 353 individual stocks and currently sits at #62 in the Zacks Industry Rank. Stocks in this group have gained about 4.46% so far this year, so KMDA is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track KMDA. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kamada Ltd. (KMDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research